Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ENDOSSEOUS BLADE IMPLANTS SHOULD REMAIN IN CLASS III, FDA PANEL SAYS; AGENCY OPEN TO FUTURE DOWNCLASSIFICATION; ROOT FORM IMPLANTS, ABUTMENTS TO CLASS II

This article was originally published in The Gray Sheet

Executive Summary

FDA is open to receiving additional data to support the downclassification of blade-type endosseous implants and is not planning to call for premarket approval applications for the devices in the near future, agency staffers say. Blade implants are the only type of endosseous devices that FDA should keep in Class III, FDA's Dental Products Advisory Panel recommended at a Jan. 13 meeting in Rockville, Maryland.

You may also be interested in...



Regulatory News In Brief

FDA export rule stayed: Agency will delay implementation of the final rule on export notification and recordkeeping requirements until June 19, according to a 1May 14 Federal Register notice. Issued in December 2001, the rule was scheduled to take effect in March (2"The Gray Sheet" Dec. 24, 2001, p 4). Three petitions and one letter stating that "certain parties would be unable to comply by the original March 19 effective date and that some parties were confused as to the final rule's applicability to certain products," prompted the agency's decision to stay the rule. The rule implements provisions of FDA's Export Reform & Enhancement Act of 1996...

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
UsernamePublicRestriction

Register

MT009453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel